	US 11,918,632 B2
	Pharmaceutical composition for diagnosing, preventing or treating liver cancer using SSU72 protein or a polynucleotide encoding the same
Chang Woo Lee, Pohang-si (KR); Jin Kwan Lee, Suwon-si (KR); Hyun Soo Kim, Seoul (KR); Jae-kyung Kim, Suwon-si (KR); and Joon Sup Yoon, Seoul (KR)
Assigned to CUROGEN TECHNOLOGY CO., LTD., Suwon-si (KR); and RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY, Suwon-si (KR)
Filed by CUROGEN TECHNOLOGY CO., LTD., Suwon-si (KR); and RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY, Suwon-si (KR)
Filed on Jul. 25, 2022, as Appl. No. 17/814,579.
Application 17/814,579 is a continuation in part of application No. PCT/IB2022/050421, filed on Jan. 19, 2022.
Claims priority of application No. 10-2021-0008251 (KR), filed on Jan. 20, 2021.
Prior Publication US 2022/0401526 A1, Dec. 22, 2022
Int. Cl. A61P 1/16 (2006.01); A61K 38/46 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01); C12N 15/861 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01)

CPC A61K 38/465 (2013.01) [A61P 1/16 (2018.01); A61P 35/00 (2018.01); C12N 15/86 (2013.01); C12Y 301/03016 (2013.01); G01N 33/57438 (2013.01); G01N 33/57484 (2013.01); G01N 33/6893 (2013.01); A61K 48/00 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01)]

6 Claims

1. A method for treating a patient suffering from liver cancer comprising administering to the patient an adeno-associated virus (AAV) vector comprising a polynucleotide encoding a Ssu72 peptide and a liver-specific promoter operably linked to the polynucleotide, and wherein the AAV vector is administered by a systemic administration or an intrahepatic administration.